GlaxoSmithKline plc (NYSE:GSK) major shareholder Plc Glaxosmithkline purchased 357,142 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was acquired at an average cost of $28.00 per share, with a total value of $9,999,976.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Plc Glaxosmithkline also recently made the following trade(s):
- On Tuesday, September 10th, Plc Glaxosmithkline purchased 177,777 shares of GlaxoSmithKline stock. The stock was acquired at an average cost of $45.00 per share, with a total value of $7,999,965.00.
NYSE GSK opened at $44.02 on Friday. The firm has a market cap of $106.05 billion, a price-to-earnings ratio of 13.93, a PEG ratio of 2.03 and a beta of 0.68. The company has a 50 day moving average of $41.97 and a 200-day moving average of $40.83. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $44.10.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Prestige Wealth Management Group LLC bought a new stake in shares of GlaxoSmithKline during the second quarter valued at approximately $26,000. Berman Capital Advisors LLC grew its stake in shares of GlaxoSmithKline by 58.1% during the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Financial Gravity Wealth Inc. grew its stake in shares of GlaxoSmithKline by 62.7% during the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 308 shares during the last quarter. Manchester Financial Inc. bought a new stake in shares of GlaxoSmithKline during the second quarter valued at approximately $39,000. Finally, Ellis Investment Partners LLC grew its stake in shares of GlaxoSmithKline by 144.5% during the third quarter. Ellis Investment Partners LLC now owns 1,022 shares of the pharmaceutical company’s stock valued at $43,000 after purchasing an additional 604 shares during the last quarter. 11.12% of the stock is owned by institutional investors.
Several research analysts recently issued reports on GSK shares. Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, October 17th. New Street Research raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Wednesday, October 16th. Societe Generale raised shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $41.79.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: What is the Beige Book?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.